Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.67
CCEL's Cash-to-Debt is ranked higher than
54% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 0.37 vs. CCEL: 0.67 )
Ranked among companies with meaningful Cash-to-Debt only.
CCEL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: No Debt Max: No Debt
Current: 0.67
Equity-to-Asset -0.63
CCEL's Equity-to-Asset is ranked lower than
99% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 0.50 vs. CCEL: -0.63 )
Ranked among companies with meaningful Equity-to-Asset only.
CCEL' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.05  Med: -0.13 Max: 0.92
Current: -0.63
-1.05
0.92
Debt-to-Equity -0.58
CCEL's Debt-to-Equity is ranked lower than
99.99% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 0.63 vs. CCEL: -0.58 )
Ranked among companies with meaningful Debt-to-Equity only.
CCEL' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.16  Med: 0 Max: 0.52
Current: -0.58
-1.16
0.52
Debt-to-EBITDA 1.76
CCEL's Debt-to-EBITDA is ranked lower than
99.99% of the 197 Companies
in the Global Medical Care industry.

( Industry Median: 2.82 vs. CCEL: 1.76 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CCEL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.88  Med: 0.47 Max: 25.22
Current: 1.76
-7.88
25.22
Interest Coverage 3.90
CCEL's Interest Coverage is ranked lower than
86% of the 224 Companies
in the Global Medical Care industry.

( Industry Median: 7.55 vs. CCEL: 3.90 )
Ranked among companies with meaningful Interest Coverage only.
CCEL' s Interest Coverage Range Over the Past 10 Years
Min: 0.46  Med: 1.92 Max: 3.9
Current: 3.9
0.46
3.9
Piotroski F-Score: 7
Altman Z-Score: 1.02
Beneish M-Score: -2.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 17.02
CCEL's Operating Margin % is ranked lower than
51% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 7.34 vs. CCEL: 17.02 )
Ranked among companies with meaningful Operating Margin % only.
CCEL' s Operating Margin % Range Over the Past 10 Years
Min: -26.76  Med: 5.43 Max: 18.83
Current: 17.02
-26.76
18.83
Net Margin % 9.87
CCEL's Net Margin % is ranked lower than
80% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 4.16 vs. CCEL: 9.87 )
Ranked among companies with meaningful Net Margin % only.
CCEL' s Net Margin % Range Over the Past 10 Years
Min: -35.1  Med: -2.03 Max: 38.43
Current: 9.87
-35.1
38.43
ROA % 12.33
CCEL's ROA % is ranked lower than
84% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 3.45 vs. CCEL: 12.33 )
Ranked among companies with meaningful ROA % only.
CCEL' s ROA % Range Over the Past 10 Years
Min: -39.68  Med: -3.05 Max: 54.57
Current: 12.33
-39.68
54.57
ROC (Joel Greenblatt) % 447.57
CCEL's ROC (Joel Greenblatt) % is ranked lower than
91% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 14.51 vs. CCEL: 447.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CCEL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -240.91  Med: 72.3 Max: 447.57
Current: 447.57
-240.91
447.57
3-Year Revenue Growth Rate 18.10
CCEL's 3-Year Revenue Growth Rate is ranked higher than
81% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 7.70 vs. CCEL: 18.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CCEL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -18  Med: 12.1 Max: 97.8
Current: 18.1
-18
97.8
GuruFocus has detected 4 Warning Signs with Cryo-Cell International Inc CCEL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CCEL's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with CCEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621999    SIC: 8099
Compare:BKK:KDH, BKK:D, XTER:MAK, TSE:6029, ASX:ZNT, NAS:CATS, NAS:JYNT, OTCPK:AMEH, BOM:526783, SGX:1D4, ROCO:4175, BOM:524520, COL:NHL.N0000, ASX:KKT, HKSE:02700, JSE:RHB, ROCO:4139, COL:AMSL.N0000, ASX:TTC, TSE:6034 » details
Headquarter Location:USA
Cryo-Cell International Inc is engaged in cellular processing & cryogenic storage. Its services include umbilical cord blood banking, umbilical cord tissue banking and umbilical cord blood & tissue banking prices.

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. It organized in two reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of Prepacyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. All the business activity of the group is functioned through United States and it derives revenue from processing and testing fees and storage fees charged each year for storage and through sales of the Prepacyte CB units.

Top Ranked Articles about Cryo-Cell International Inc

Cryo-Cell Reports Fiscal Third Quarter 2017 Results
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2017 Financial Results
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2017 Financial Results
Cryo-Cell Reports Financial Results for Fiscal 2016

OLDSMAR, Fla., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTCQB:CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year 2016.  
Financial Results Revenue Consolidated revenues for fiscal 2016 were approximately $23.1 million compared to approximately $21.1 million for fiscal 2015.  The revenues for fiscal 2016 consisted of approximately $21.8 million in processing and storage fee revenue, $1.0 million in licensee income, and $350,000 in product revenue compared to approximately $19.6 million in processing and storage fee revenue, approximately $1.0 million in licensee income and $471,000 in product revenue for fiscal 2015.  Net (Loss) Income The Company reported a net loss in fiscal 2016 of ($1.3) million, or ($0.16) per basic share, compared to net income of $8.1 million, or $0.85 per basic share and $0.83 per diluted share, in fiscal 2015.  The net loss in fiscal 2016 resulted from the cancellation of certain interests in the Florida Revenue Sharing Agreement and certain interests in the Texas Revenue Sharing Agreement resulting in loss on extinguishment of revenue sharing agreements in the amount of $2.3 million, goodwill and intangible assets impairment of $2.0 million, a 19% increase in selling, general and administrative expenses and a 3% increase in cost of sales.  This was offset by a 10% increase in total revenue and an income tax benefit of approximately $1,159,000.  During fiscal 2015, the Company released approximately $8.2 million of its valuation allowance for income taxes.  Cash and Cash Equivalent Position
           
As of November 30, 2016, the Company had cash and cash equivalents of $3.5 million.  The Company’s cash decreased by approximately $652,000 during fiscal 2016, primarily as a result of approximately $10.8 million used for stock repurchases offset by cash flow from operations of approximately $5.0 million and an increase in total debt to approximately $10.2 million.  About Cryo-Cell International, Inc. Founded in 1989, Cryo-Cell International, Inc. is the world's first private cord blood bank.  More than 500,000 parents from 87 countries trust Cryo-Cell to preserve their family members' stem cells.  Cryo-Cell's mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine. Cryo-Cell operates in a facility that is FDA registered, cGMP-/cGTP-compliant and is licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell is also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. In addition, Cryo-Cell is ISO 9001:2008 certified by BSI, an internationally recognized, quality assessment organization. Cryo-Cell is a publicly traded company, OTCQB:CCEL. For more information, please visit www.cryo-cell.com.  Forward-Looking Statement Statements wherein the terms “believes”, “intends”, “projects”, “anticipates”, “expects”, and similar expressions as used are intended to reflect “forward-looking statements” of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the success of the Company’s global expansion initiatives and product diversification, the Company’s actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company’s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company’s business, the Company’s ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations, the success and enforceability of the Company’s menstrual stem cell technology license agreements and umbilical cord blood license agreements and their ability to provide the Company with royalty fees, the ability of the reproductive tissue storage to generate new revenues for the Company and those risks and uncertainties contained in risk factors described in documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.
Contact:

David Portnoy
Cryo-Cell International, Inc.
813-749-2100
[email protected]


Read more...

Ratios

vs
industry
vs
history
PE Ratio 25.93
CCEL's PE Ratio is ranked lower than
99.99% of the 200 Companies
in the Global Medical Care industry.

( Industry Median: 26.57 vs. CCEL: 25.93 )
Ranked among companies with meaningful PE Ratio only.
CCEL' s PE Ratio Range Over the Past 10 Years
Min: 3.44  Med: 12.84 Max: 114
Current: 25.93
3.44
114
PE Ratio without NRI 25.93
CCEL's PE Ratio without NRI is ranked lower than
99.99% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 26.50 vs. CCEL: 25.93 )
Ranked among companies with meaningful PE Ratio without NRI only.
CCEL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 3.44  Med: 12.84 Max: 114
Current: 25.93
3.44
114
Price-to-Owner-Earnings 12.10
CCEL's Price-to-Owner-Earnings is ranked lower than
69% of the 106 Companies
in the Global Medical Care industry.

( Industry Median: 26.22 vs. CCEL: 12.10 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CCEL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.55  Med: 10.5 Max: 109.78
Current: 12.1
2.55
109.78
PS Ratio 2.34
CCEL's PS Ratio is ranked lower than
59% of the 259 Companies
in the Global Medical Care industry.

( Industry Median: 1.70 vs. CCEL: 2.34 )
Ranked among companies with meaningful PS Ratio only.
CCEL' s PS Ratio Range Over the Past 10 Years
Min: 0.28  Med: 1.34 Max: 2.4
Current: 2.34
0.28
2.4
Price-to-Free-Cash-Flow 9.37
CCEL's Price-to-Free-Cash-Flow is ranked higher than
90% of the 124 Companies
in the Global Medical Care industry.

( Industry Median: 22.48 vs. CCEL: 9.37 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CCEL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.05  Med: 11.29 Max: 218.46
Current: 9.37
4.05
218.46
Price-to-Operating-Cash-Flow 9.22
CCEL's Price-to-Operating-Cash-Flow is ranked higher than
77% of the 179 Companies
in the Global Medical Care industry.

( Industry Median: 14.62 vs. CCEL: 9.22 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CCEL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.33  Med: 10.75 Max: 277
Current: 9.22
3.33
277
EV-to-EBIT 13.80
CCEL's EV-to-EBIT is ranked lower than
99.99% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 20.85 vs. CCEL: 13.80 )
Ranked among companies with meaningful EV-to-EBIT only.
CCEL' s EV-to-EBIT Range Over the Past 10 Years
Min: -94.8  Med: 2.4 Max: 142.6
Current: 13.8
-94.8
142.6
EV-to-EBITDA 13.07
CCEL's EV-to-EBITDA is ranked lower than
99.99% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 15.17 vs. CCEL: 13.07 )
Ranked among companies with meaningful EV-to-EBITDA only.
CCEL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -161.4  Med: 2.6 Max: 177.4
Current: 13.07
-161.4
177.4
EV-to-Revenue 2.33
CCEL's EV-to-Revenue is ranked higher than
51% of the 265 Companies
in the Global Medical Care industry.

( Industry Median: 2.18 vs. CCEL: 2.33 )
Ranked among companies with meaningful EV-to-Revenue only.
CCEL' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 1.1 Max: 2.6
Current: 2.33
0.1
2.6
Shiller PE Ratio 211.82
CCEL's Shiller PE Ratio is ranked lower than
98% of the 55 Companies
in the Global Medical Care industry.

( Industry Median: 27.79 vs. CCEL: 211.82 )
Ranked among companies with meaningful Shiller PE Ratio only.
CCEL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 166.5  Med: 199.5 Max: 350
Current: 211.82
166.5
350
Current Ratio 0.87
CCEL's Current Ratio is ranked lower than
77% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 1.41 vs. CCEL: 0.87 )
Ranked among companies with meaningful Current Ratio only.
CCEL' s Current Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.37 Max: 35.3
Current: 0.87
0.47
35.3
Quick Ratio 0.84
CCEL's Quick Ratio is ranked lower than
72% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 1.31 vs. CCEL: 0.84 )
Ranked among companies with meaningful Quick Ratio only.
CCEL' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.37 Max: 35.3
Current: 0.84
0.47
35.3
Days Inventory 18.90
CCEL's Days Inventory is ranked lower than
57% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 16.86 vs. CCEL: 18.90 )
Ranked among companies with meaningful Days Inventory only.
CCEL' s Days Inventory Range Over the Past 10 Years
Min: 2.07  Med: 17.5 Max: 26.45
Current: 18.9
2.07
26.45
Days Sales Outstanding 71.60
CCEL's Days Sales Outstanding is ranked lower than
82% of the 220 Companies
in the Global Medical Care industry.

( Industry Median: 41.26 vs. CCEL: 71.60 )
Ranked among companies with meaningful Days Sales Outstanding only.
CCEL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.43  Med: 55.27 Max: 73.85
Current: 71.6
46.43
73.85
Days Payable 76.20
CCEL's Days Payable is ranked higher than
58% of the 159 Companies
in the Global Medical Care industry.

( Industry Median: 51.14 vs. CCEL: 76.20 )
Ranked among companies with meaningful Days Payable only.
CCEL' s Days Payable Range Over the Past 10 Years
Min: 49.91  Med: 84.36 Max: 104.76
Current: 76.2
49.91
104.76

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 14.20
CCEL's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 159 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. CCEL: 14.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CCEL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.9  Med: -0.4 Max: 14.2
Current: 14.2
-14.9
14.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 3.23
CCEL's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
81% of the 103 Companies
in the Global Medical Care industry.

( Industry Median: 1.98 vs. CCEL: 3.23 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CCEL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2.46  Med: 6.27 Max: 90
Current: 3.23
2.46
90
Price-to-Median-PS-Value 1.74
CCEL's Price-to-Median-PS-Value is ranked lower than
78% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 1.03 vs. CCEL: 1.74 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CCEL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.29  Med: 1.25 Max: 67.6
Current: 1.74
0.29
67.6
Earnings Yield (Greenblatt) % 7.25
CCEL's Earnings Yield (Greenblatt) % is ranked lower than
81% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 3.79 vs. CCEL: 7.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CCEL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -95.3  Med: 6.9 Max: 642.2
Current: 7.25
-95.3
642.2

More Statistics

Revenue (TTM) (Mil) $24.78
EPS (TTM) $ 0.30
Beta-0.37
Short Percentage of Float0.00%
52-Week Range $3.85 - 7.99
Shares Outstanding (Mil)7.10

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}